Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs.…
| Métrica | ZEAL.CO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 100.0% | 57.4% | +42.6% |
| Operating Margin | 75.5% | -34.4% | +109.9% |
| Net Margin | 70.0% | -32.5% | +102.5% |
| FCF Margin | 70.5% | -12.6% | +83.1% |
| ROE | 43.5% | -39.2% | +82.7% |
| ROA | 40.5% | -30.9% | +71.4% |
| Current Ratio | 23.57 | 2.73 | +20.84 |
| Debt / Equity | 0.02 | 0.28 | -0.26 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 40.5% | — |
| ✓Flujo de caja operativo positivo | DKK 6.5B | −DKK 931M |
| ✓Rentabilidad sobre activos al alza | 40.5% | -11.3% |
| ✓Caja operativa/activos supera al ROA | 41.0% | ROA 40.5% |
| ✓Menos deuda a largo plazo | 1.9% | 3.0% |
| ✓Mejor liquidez (ratio corriente) | 23.57 | 21.14 |
| ✗Sin aumentar el nº de acciones | 72M | 66M |
| ✓Margen bruto al alza | 100.0% | 87.4% |
| ✓Rotación de activos al alza | 0.58 | 0.01 |
| Calidad del negocio | FY25 |
|---|---|
| ✓Margen FCF > 10 % | 70.5% |
| ✓ROCE > 10 % | 45.5% |
| ✓Ventas > 5 %/año (3 años) | 345.8% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 17.8% |
Riesgo de quiebra (Altman Z 11.2): zona segura
ZEALAND PHARMA A/S cotiza a 226.30 DKK y tiene una capitalización bursátil de DKK 15.0B. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud